Emergent Biosolutions
EBS
233 hedge funds and large institutions have $2.22B invested in Emergent Biosolutions in 2019 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 93 increasing their positions, 87 reducing their positions, and 61 closing their positions.
23% more call options, than puts
Call options by funds: $53K | Put options by funds: $43K
7% more repeat investments, than reductions
Existing positions increased: 93 | Existing positions reduced: 87
0.94% more ownership
Funds ownership: 88.32% → 89.26% (+0.94%)
3% less capital invested
Capital invested by funds: $2.28B → $2.22B (-$68.6M)
14% less funds holding
Funds holding: 272 → 233 (-39)
56% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 61
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EARNEST Partners
Atlanta,
Georgia
|
+$72.7M |
| 2 |
Lazard Asset Management
New York
|
+$34.5M |
| 3 |
Jennison Associates
New York
|
+$17.9M |
| 4 |
Goldman Sachs
New York
|
+$16.2M |
| 5 |
State Street
Boston,
Massachusetts
|
+$15.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$30.1M |
| 2 |
GT
Glenmede Trust
Philadelphia,
Pennsylvania
|
-$29.1M |
| 3 |
Man Group
London,
United Kingdom
|
-$17.5M |
| 4 |
FA
Friess Associates
Greenville,
Delaware
|
-$12.9M |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$11M |
EBS Hedge Fund Activity: Q2 2019 in Review
233 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Emergent Biosolutions (EBS) for Q2 2019, worth a combined $2.22B — down 3% from $2.28B a quarter earlier.
Sellers outnumbered buyers: 61 funds closed out of EBS and 27 opened new positions — a net loss of 34 holders — while 87 trimmed existing stakes and 93 added.
The largest buyer was EARNEST Partners, adding an estimated $72.7M. The largest seller was Renaissance Technologies, cutting an estimated $30.1M.
- 233 institutional investors held Emergent Biosolutions (EBS) as of Q2 2019, down from 272 in Q1 2019.
- Funds reported $2.22B of Emergent Biosolutions stock for Q2 2019, down 3% quarter-over-quarter.
- 27 funds opened new Emergent Biosolutions positions in Q2 2019 and 61 closed out, a net change of -34 holders.
- The largest Emergent Biosolutions buyer in Q2 2019 was EARNEST Partners, an estimated $72.7M added.
- The largest Emergent Biosolutions seller in Q2 2019 was Renaissance Technologies, an estimated $30.1M sold.
Based on aggregated 13F filings for Q2 2019.